CN1339318A - Method for treating AIDS and its preparing method - Google Patents
Method for treating AIDS and its preparing method Download PDFInfo
- Publication number
- CN1339318A CN1339318A CN00123483A CN00123483A CN1339318A CN 1339318 A CN1339318 A CN 1339318A CN 00123483 A CN00123483 A CN 00123483A CN 00123483 A CN00123483 A CN 00123483A CN 1339318 A CN1339318 A CN 1339318A
- Authority
- CN
- China
- Prior art keywords
- epitope
- medicine
- aids
- eldkwa
- immune deficiency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000030507 AIDS Diseases 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title claims description 13
- 239000003814 drug Substances 0.000 claims abstract description 33
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 18
- 229920001184 polypeptide Polymers 0.000 claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 18
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims abstract description 16
- 230000008878 coupling Effects 0.000 claims abstract description 13
- 238000010168 coupling process Methods 0.000 claims abstract description 13
- 238000005859 coupling reaction Methods 0.000 claims abstract description 13
- 239000002671 adjuvant Substances 0.000 claims abstract description 11
- 239000000427 antigen Substances 0.000 claims abstract description 5
- 102000036639 antigens Human genes 0.000 claims abstract description 5
- 108091007433 antigens Proteins 0.000 claims abstract description 5
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 4
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims abstract description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 34
- 208000011580 syndromic disease Diseases 0.000 claims description 24
- 230000036039 immunity Effects 0.000 claims description 11
- 210000004408 hybridoma Anatomy 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000007910 cell fusion Effects 0.000 claims description 4
- 238000011091 antibody purification Methods 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 5
- 230000007812 deficiency Effects 0.000 abstract description 3
- 230000003053 immunization Effects 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940124321 AIDS medicine Drugs 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- -1 succinimide ester Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The AIDS treating medicine of the present invention includes at least a kind of monoclonal antibody, the antigen of which is ELDKWA neutralizing epitope and its variation epitopes ELEKWA, ELNKWA and ELDEWAF of human immune deficiency virus transmembrane protein gp41. It is prepared through the steps of: artificial synthesis of at least one polypeptide containing ELDKWA neutralizing epitope and/or its variation epitopes of human immune deficiency virus transmembrane protein gp41; coupling the said polypeptide to carrier protein or carrier polypeptide; immunizing animal with the said conjugate; preparing hybrid tumor; and compounding the obtained antibody with medicinal adjuvant to obtain the medicine.
Description
The present invention relates to medicine with the treatment acquired immune deficiency syndrome (AIDS) of biotechnology preparation and preparation method thereof, particularly relate to medicine with the treatment acquired immune deficiency syndrome (AIDS) of the Monoclonal Antibody of HIV (human immunodeficiency virus) (Human Immunodeficiency Virus) memebrane protein and preparation method thereof.
Acquired immune deficiency syndrome (AIDS) claims acquired immune deficiency syndrome (AIDS) again, is a kind of immune disease that is caused by HIV (human immunodeficiency virus) (HIV).Because it is propagated rapidly, case fatality rate is high, and does not still have the specific treatment method at present, does not more have vaccine and can prevent, thereby the title of " 20 century plague " is arranged.
Existingly be used for only deferrable period of disease and prolong patient's life of clinical anti-AIDS drug, and cost an arm and a leg, toxicity is big.Recently external anti-AIDS drug clinical research result proves, the mucosa that can suppress HIV-1 virus at neutralizing antibody (comprising the monoclonal antibody 2F5 of ELDKWA-epitope specificity) being used in combination in passive immunotherapy of the several specific neutralizing epitopes on the HIV-1 memebrane protein gp160 (precursor protein of memebrane protein gp120 and transmembrane protein gp41) infects and mother-to-baby transmission, and can remove HIV-1 virus (Nature Medicine 1999,5:204 in the blood; Nature Medicine 2000,6:200; Nature Medicine1999,5:211); The epitope specificity monoclonal antibody of main neutralizing epitope ELDKWA on human immunodeficiency virus (HIV-1) the transmembrane protein gp41 can the multiple HIV-1 Strain of vitro inhibition target cell infection (J.Virology 1993,67:6642; AIDS Res.Human Retroviruses 1994,10:1651; AIDS1996,10:587).
The medicine that the purpose of this invention is to provide a kind of effective treatment acquired immune deficiency syndrome (AIDS), this medicine can tackle the variation of HIV (human immunodeficiency virus) (Human Immunodeficiency Virus).
Another object of the present invention provides a kind of method for preparing the medicine of above-mentioned treatment acquired immune deficiency syndrome (AIDS).
For achieving the above object, the present invention takes following design: a kind of medicine for the treatment of acquired immune deficiency syndrome (AIDS), and it consists essentially of at least a monoclonal antibody, and the antigen of described antibody is ELDKWA epi-position and the variant epitope thereof on human immunodeficiency virus's transmembrane protein gp41.
Described variant epitope is ELEKWA, ELNKWA or ELDEWA.
It is preferably composed of the following components that the present invention treats the medicine of acquired immune deficiency syndrome (AIDS):
The monoclonal antibody of ELDKWA-epitope specificity
The monoclonal antibody of ELEKWA-epitope specificity
The monoclonal antibody of ELNKWA-epitope specificity
The monoclonal antibody of ELDEWA-epitope specificity
A kind of method for preparing the medicine of above-mentioned treatment acquired immune deficiency syndrome (AIDS) consists essentially of following steps:
(1), synthetic at least one contains the epitope polypeptide of the neutralizing epitope on human immunodeficiency virus's transmembrane protein gp41 respectively, described neutralizing epitope be selected from the ELDKWA epi-position or/and its variant epitope or at least once multiple ELDKWA epi-position or/and its variant epitope;
(2), above-mentioned epitope polypeptide is coupled to respectively on carrier protein or the carrier polypeptide forms coupling matter;
(3), be equipped with acceptable adjuvant immunity animal respectively with above-mentioned coupling matter;
(4), adopt conventional cell-fusion techniques to prepare hybridoma respectively;
(5), the antibody purification that will obtain from above-mentioned different hybridoma cell lines, be mixed and made into the medicine of treatment acquired immune deficiency syndrome (AIDS).
Wherein, at least one polypeptide of described synthetic is preferably: contain at least once multiple neutralizing epitope ELDKWA or its variant epitope on human immunodeficiency virus's transmembrane protein gp41 respectively.
The variant epitope of described ELDKWA epi-position is ELEKWA, ELNKWA or ELDEWA.
Studies show that, in treating AIDS, can reduce the carrying capacity of virus, delay the carrying out of disease at the antibody of neutralizing epitope on the HIV-1 memebrane protein.The medicine that the present invention treats acquired immune deficiency syndrome (AIDS) is the medicine that contains the multiple antibody of main neutralizing epitope ELDKWA epi-position on the anti human immune deficiency virus transmembrane protein gp41 and variant epitope (as ELEKWA, ELNKWA, ELDEWA) thereof, even produce in HIV (human immunodeficiency virus) (Human Immunodeficiency Virus) under the situation of variation, injected in the human body of this medicine and also had the virus that corresponding antibody is killed variation.
Medicine of the present invention is avirulence not only, and in the immunization therapy effect that improves acquired immune deficiency syndrome (AIDS), also can reduce the treating AIDS cost.
The present invention adopts the method for synthetic epitope polypeptide to induce, prepare the monoclonal antibody of predetermined epitope specificity, overcome and need utilize native protein or recombiant protein immunity, a large amount of then screenings and evaluation just can obtain many complex work of the monoclonal antibody of predetermined epitope specificity.
According to the present invention, can produce the medicine of its respective type very soon according to the variation situation of HIV (human immunodeficiency virus) (Human Immunodeficiency Virus), need not test for a long time, reduce production costs.This technology will produce significant impact to world's preventive medicine research, and will bring huge economic benefit and social benefit.
The invention will be further described below in conjunction with non-limiting specific embodiment.
Embodiment one: by the variant epitope ELNKWA-epitope specificity antibody of the neutralizing epitope ELDKWA on the anti-HIV-1 gp41 is the medicine of the treatment acquired immune deficiency syndrome (AIDS) made of main active, by following steps production:
(1), one of synthetic contains the epitope polypeptide of 4 multiple ELNKWA neutralizing epitopes on human immunodeficiency virus's transmembrane protein gp41
CELNKWAGELNKWAGELNKWAGELNKWA；
(2), utilize MBS (m-maleimidobenzoyl-N-hydoxy succinimide ester) with above-mentioned epitope polypeptide and carrier protein BSA coupling connection;
(3), above-mentioned coupling matter is mixed with freund adjuvant that (volume ratio of two kinds of materials is coupling matter: immune Balb/c mice freund adjuvant=1: 1).Use for the first time complete freund adjuvant, later per two all immunity once, full freund adjuvant toos many or too much for use.The antigen dose of each immunity is: contain the coupling matter of 10 microgram epitope polypeptides/time/only, immunity is 3 times altogether;
(4), adopt conventional cell-fusion techniques to merge the mouse boosting cell after the immunity and mouse myeloma cell line, and the preparation hybridoma;
(5), from above-mentioned hybridoma cell line, filter out the clone that can produce the monoclonal antibody of predefined epitope specificity, the antibody of purifying is made the medicine of treatment acquired immune deficiency syndrome (AIDS).
This medicine using dosage is in actual applications determined according to patient's the state of an illness.
Embodiment two: by the antibody of the neutralizing epitope ELDKWA on the anti-HIV-1 gp41 and variant epitope ELNKWA, ELEKWA and ELDEWA is the medicine of the treatment acquired immune deficiency syndrome (AIDS) made of main active, by following steps production:
(1), 4 of synthetic contain neutralizing epitope ELDKWA on human immunodeficiency virus's transmembrane protein gp41 and the polypeptide of variant epitope ELNKWA, ELEKWA or ELDEWA thereof respectively:
C?ELDKWA?G?ELDKWA?G?ELDKWA?G?ELDKWA
C?ELNKWA?G?ELNKWA?G?ELNKWA?G?ELNKWA
C?ELEKWA?G?ELEKWA?G?ELEKWA?G?ELEKWA
C?ELDEWA?G?ELDEWA?G?ELDEWA?G?ELDEWA
(2), utilize glutaraldehyde or MBS that aforementioned polypeptides is coupled to respectively on the carrier protein bovine serum albumin and form coupling matter;
(3), above-mentioned coupling matter is mixed with freund adjuvant respectively (volume ratio of two kinds of materials is coupling matter: freund adjuvant=1: 1), immune Balb/c mice respectively.Use for the first time complete freund adjuvant, later per two all immunity once, full freund adjuvant toos many or too much for use.The antigen dose of each immunity is: contain the coupling matter of 10 microgram epitope polypeptides/time/only, immunity is 3 times altogether;
(4), adopt conventional cell-fusion techniques to merge the mouse boosting cell after the immunity and mouse myeloma cell line, and the preparation hybridoma;
(5), filter out the clone that can produce the monoclonal antibody of predefined 4 kinds of epitope specificities from above-mentioned hybridoma cell line.
(6), obtain 4 kinds of monoclonal antibodies of neutralizing epitope ELDKWA on the anti-HIV-1 gp41 and variant epitope ELNKWA, ELEKWA, ELDEWA respectively from above-mentioned hybridoma cell line, above-mentioned antibody is mixed, make the medicine of treatment acquired immune deficiency syndrome (AIDS), wherein, the probability of occurrence of the various epi-positions that drawn by the statistical procedures that is suitable for the crowd of the addition of various antibody is adjusted.
Use medicine of the present invention, can obviously resist the variation of HIV (human immunodeficiency virus) (Human Immunodeficiency Virus), reduce the carrying capacity of HIV (human immunodeficiency virus) (Human Immunodeficiency Virus), delay the carrying out of disease, reach the purpose of healing at last.
Claims (6)
1, a kind of medicine for the treatment of acquired immune deficiency syndrome (AIDS), it consists essentially of at least a monoclonal antibody, and the antigen of described antibody is ELDKWA epi-position and the variant epitope thereof on human immunodeficiency virus's transmembrane protein gp41.
2, a kind of medicine for the treatment of acquired immune deficiency syndrome (AIDS) according to claim 1, it is characterized in that: described variant epitope is ELEKWA, ELNKWA or ELDEWA.
3, a kind of medicine for the treatment of acquired immune deficiency syndrome (AIDS) according to claim 1 and 2, it is characterized in that: it is composed of the following components: the monoclonal antibody of ELDKWA-epitope specificity
The monoclonal antibody of ELEKWA-epitope specificity
The monoclonal antibody of ELNKWA-epitope specificity
The monoclonal antibody of ELDEWA-epitope specificity
4, a kind of method for preparing the medicine of the described treatment acquired immune deficiency syndrome (AIDS) of claim 1-3 consists essentially of following steps:
(1), synthetic at least one contains the epitope polypeptide of the neutralizing epitope on human immunodeficiency virus's transmembrane protein gp41 respectively, described neutralizing epitope be selected from the ELDKWA epi-position or/and its variant epitope or at least once multiple ELDKWA epi-position or/and its variant epitope;
(2), above-mentioned epitope polypeptide is coupled to respectively on carrier protein or the carrier polypeptide forms coupling matter;
(3), be equipped with acceptable adjuvant immunity animal respectively with above-mentioned coupling matter;
(4), adopt conventional cell-fusion techniques to prepare hybridoma respectively;
(5), the antibody purification that will obtain from above-mentioned different hybridoma cell lines, be mixed and made into the medicine of treatment acquired immune deficiency syndrome (AIDS).
5, the method for the medicine of preparation treatment acquired immune deficiency syndrome (AIDS) according to claim 4, it is characterized in that: at least one polypeptide of described synthetic contains at least once multiple neutralizing epitope ELDKWA or its variant epitope on human immunodeficiency virus's transmembrane protein gp41 respectively.
6, according to the method for the medicine of claim 4 or 5 described preparations treatment acquired immune deficiency syndrome (AIDS), it is characterized in that: the variant epitope of described ELDKWA epi-position is ELEKWA, ELNKWA or ELDEWA.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001234838A CN1172717C (en) | 2000-08-18 | 2000-08-18 | Method for treating AIDS and its preparing method |
| PCT/CN2001/001192 WO2002032452A1 (en) | 2000-08-18 | 2001-07-20 | Composition for aids and method producing it |
| AU2002214920A AU2002214920A1 (en) | 2000-08-18 | 2001-07-20 | Composition for aids and method producing it |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001234838A CN1172717C (en) | 2000-08-18 | 2000-08-18 | Method for treating AIDS and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1339318A true CN1339318A (en) | 2002-03-13 |
| CN1172717C CN1172717C (en) | 2004-10-27 |
Family
ID=4589903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001234838A Expired - Fee Related CN1172717C (en) | 2000-08-18 | 2000-08-18 | Method for treating AIDS and its preparing method |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1172717C (en) |
| AU (1) | AU2002214920A1 (en) |
| WO (1) | WO2002032452A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327897C (en) * | 2002-09-24 | 2007-07-25 | 重庆前沿生物技术有限公司 | Peptide derivative fusion inhibitors of HIV infection |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108779168A (en) | 2015-12-05 | 2018-11-09 | 沃迪奥斯大学医院中心 | HIV bonding agents |
| WO2020012435A1 (en) | 2018-07-13 | 2020-01-16 | Lausanne University Hospital | Hiv binding agents |
| US20220267416A1 (en) | 2019-07-15 | 2022-08-25 | Lausanne University Hospital | Hiv binding agents |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5459060A (en) * | 1989-08-24 | 1995-10-17 | Bioclonetics Incorporated | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) |
| WO1994012533A1 (en) * | 1992-11-23 | 1994-06-09 | President And Fellows Of Harvard College | Gp41 mutants and their use as hiv therapeutics |
| CN1111540C (en) * | 1993-06-09 | 2003-06-18 | 康诺特实验室有限公司 | Placed in-line synthetic HIV-1 peptide class |
| US5380668A (en) * | 1993-07-06 | 1995-01-10 | University Of Utah Research Foundation | Compounds having the antigenicity of hCG |
| JPH09502348A (en) * | 1993-09-11 | 1997-03-11 | ポリムン・シエンティフィーク・イムノビオロギッシェ・フォルシュング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Peptides for inducing neutralizing antibodies against genetically branched HIV-1 strains |
-
2000
- 2000-08-18 CN CNB001234838A patent/CN1172717C/en not_active Expired - Fee Related
-
2001
- 2001-07-20 WO PCT/CN2001/001192 patent/WO2002032452A1/en active Application Filing
- 2001-07-20 AU AU2002214920A patent/AU2002214920A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327897C (en) * | 2002-09-24 | 2007-07-25 | 重庆前沿生物技术有限公司 | Peptide derivative fusion inhibitors of HIV infection |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002214920A1 (en) | 2002-04-29 |
| WO2002032452A1 (en) | 2002-04-25 |
| CN1172717C (en) | 2004-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20030003440A1 (en) | Novel CCR5 epitope and antibodies against it | |
| AT398080B (en) | IMMORTALIZED CELL LINE, METHOD FOR THEIR PRODUCTION AND METHOD FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES, AND DIAGNOSTIC METHODS AND MEANS | |
| JPH06502539A (en) | Neutralizing human monoclonal antibody specific for the V3 loop and CD-4 binding site of HIV-1 GP120 | |
| WO1996033219A1 (en) | Monoclonal antibodies against hiv-1 and vaccines made thereof | |
| US20080248531A1 (en) | Preparation of fully human antibodies | |
| US6132721A (en) | Non-Toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing same | |
| JPH09509164A (en) | Compositions and methods for preventing and treating inflammation with immunoglobulin A | |
| WO2012018284A1 (en) | Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids | |
| KR930702509A (en) | Human immunodeficiency virus (HIV) immunotherapy | |
| CN1172717C (en) | Method for treating AIDS and its preparing method | |
| US6200575B1 (en) | Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them | |
| WO2001060156A1 (en) | Neutralizing antibody and immunomodulatory enhancing compositions | |
| JPH04506666A (en) | LFA-3 as a vaccine adjuvant | |
| EP0719281B1 (en) | Multiple branch peptide constructions for use against hiv | |
| CN1339319A (en) | Medicine for treating AIDS and its preparing method | |
| WO1991010742A1 (en) | Monoclonal antibody specific for non-immunodominant epitope of hiv proteins | |
| CN1339320A (en) | AIDS vacuum and its preparing method and use | |
| CA2481325C (en) | Anti-hiv composition, production method thereof and medicament | |
| AP255A (en) | A method of inoculation with an antigenic peptide. | |
| CN1238499C (en) | Antibody against AIDS virus O and its production cell series and use | |
| JP2001505763A (en) | HIV P-17 peptide fragment, composition containing the same, and methods for producing and using the same | |
| CA2171531C (en) | Multiple branch peptide constructions for use against hiv | |
| JP3725899B2 (en) | Multi-branched peptide constructs for use against HIV | |
| EP1366080B1 (en) | Natural antibodies active against hiv virus | |
| WO1998001476A1 (en) | Highly synergistic neutralization of hiv through combinations of monoclonal and polyclonal antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |